These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29939507)

  • 1. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
    Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
    Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coverage of New Drugs in Medicare Part D.
    Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
    Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
    Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis.
    Hohmann N; Hansen R; Garza KB; Harris I; Kiptanui Z; Qian J
    Value Health; 2018 Oct; 21(10):1186-1191. PubMed ID: 30314619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between FDA black box warnings and Medicare formulary coverage changes.
    Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
    Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
    Jackson EA; Axelsen KJ
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Formulary Exclusions and Restrictions for Opioid Alternatives With Opioid Prescribing Among Medicare Beneficiaries.
    Rao T; Kiptanui Z; Dowell P; Triebwasser C; Alexander GC; Harris I
    JAMA Netw Open; 2020 Mar; 3(3):e200274. PubMed ID: 32119095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of formulary restrictions on medication intensification in diabetes treatment.
    Stuart BC; Slejko JF; Rueda JD; Cooke CE; Shen X; Roberto P; Ciarametaro M; Dubois R
    Am J Manag Care; 2018 May; 24(5):239-246. PubMed ID: 29851442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of formulary restrictions on medication use and costs.
    Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
    Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011-20.
    Joyce G; Blaylock B; Chen J; Van Nuys K
    Health Aff (Millwood); 2024 Mar; 43(3):391-397. PubMed ID: 38437610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of orphan drug coverage restrictions in Medicare Part D.
    Yehia F; Segal JB; Anderson GF
    Am J Manag Care; 2020 Sep; 26(9):e289-e294. PubMed ID: 32930558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constraints on Formulary Design Under the Affordable Care Act.
    Andersen M
    Health Econ; 2017 Dec; 26(12):e160-e178. PubMed ID: 28233420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders.
    Donohue JM; Frank RG
    Psychiatr Serv; 2007 Oct; 58(10):1285-91. PubMed ID: 17914004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare program: Medicare Advantage and prescription drug programs MIPPA drug formulary & protected classes policies. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2009 Jan; 74(11):2881-8. PubMed ID: 19385109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug plan design incentives among Medicare prescription drug plans.
    Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
    Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Coverage Restrictions on Antipsychotic Utilization Among Low-Income Medicare Part D Enrollees.
    Roberto PN; Brandt N; Onukwugha E; Perfetto E; Powers C; Stuart B
    Adm Policy Ment Health; 2017 Nov; 44(6):943-954. PubMed ID: 28660370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.